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Abstract
Background: Hepatocellular carcinoma (HCC), the most common type of liver cancer accounts for more than one
million deaths worldwide. Current treatment modality for HCC is marginally effective. Plants belonging to Mistletoe
family (Loranthaceae) have been used in chemotherapy for many years. The present study was aimed at exploring
the anti-proliferative, pro-oxidant and pro-apoptotic potential of stem of Elytranthe parasitica (L.) Danser (EP), a
parasitic shrub belonging to Loranthaceae.
Methods: Elytranthe parasitica (L.) Danser, a climbing parasitic shrub was investigated for its cytotoxic activity
against HepG2, a hepatocellular carcinoma cell line by Sulforhodamine B (SRB) assay. Further, pro-oxidant activity of
EP extract/fractions was studied using copper phenanthroline assay. To understand the mechanism of cell death,
the pro-apoptotic effects of Hep-G2 cells treated with EP extract/fractions were visualized by dual staining using
acridine orange and ethidium bromide, a morphological marker of apoptosis. Phytochemical profiling of EP was
explored by estimating the phenol, flavonoid and tannin content in its various fractions and extract. The occurrence
of gallic acid, a principal polyphenol in EP extract and fractions was detected and further quantified using HPTLC
(High Performance Thin Layer Chromatography) fingerprinting.
Result: Active fraction of Elytranthe parasitica, EP.DEE exhibited potent cytotoxic activity in a dose dependent
manner against HepG2 hepatocellular carcinoma cell line with an IC50 of 56.7 ± 7.8 μg/mL. Dual staining with
acridine orange and ethidium bromide revealed that HepG2 cells treated with EP active fractions underwent cell
death chiefly by apoptosis. Highest phenol, flavonoid and tannin content were observed in active fractions, EP.EA
(Ethyl acetate fraction) and EP.DEE (Diethyl ether fraction). Gallic acid was identified and quantified in EP extract and
active fractions, EP.DEE and EP.EA.
Conclusion: Our findings indicate EP active fraction could be a promising contender in the treatment of
hepatocellular carcinoma.
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Background
Hepatocellular carcinoma (HCC) is the most frequent
and fatal type of liver cancer – a cancer that arises when
a cell in the liver becomes genetically mutated allowing
it to grow relentlessly [1]. The Cancer Statistics Report
2016 has recounted a higher incidence and mortality
rate chiefly due to cancer of the liver [2]. With approxi-
mately five lakh new cases being diagnosed every year,
HCC has become the fifth most common cause of can-
cer worldwide [3]. In India, death due to HCC has been
on a rise in the recent years with a mortality rate of 6.8
per 100, 000 in men and 5.1 per 100,000 in women [4].
More often, patients diagnosed with HCC have very low
survival rate, with merely 17.2 % of them surviving for
5 years or more after diagnosis [5]. Common treatment
strategies for HCC include hepatectomy, liver transplant-
ation, radiofrequency ablation (RFA), radiotherapy and
chemotherapy [6]. Standard chemotherapy treatment in-
volves administration of Sorafenib or Nexavar, a MAP
Kinase inhibitor. Patients on Nexavar generally encounter
adverse drug effects such as diarrhea, hand-foot skin dis-
ease, fatigue, anorexia and alopecia [7]. Medicinal plants
and natural products, which have considerable chemother-
apeutic value and comparatively fewer side effects [8–10],
are increasingly being studied for treating cancer.
Elytranthe parasitica (L.) Danser [Synonym: Macroso-
len parasitica (L.) Danser] is a perennial climbing woody
parasitic shrub that belongs to Loranthaceae, the largest
mistletoe family [11]. Known locally as Bandanekke or
Baranike in Karnataka [12], this plant grows widely in
the Western Ghats of India on peepal, mango, neem and
jackfruit trees [13]. Mistletoes have a strong ethnopharma-
cological track record in the treatment of cancer [14, 15].
A primary example of this is Viscum Album or European
mistletoe, that contains numerous chemopreventive and
cytotoxic compounds such as lectins, viscotoxins and fla-
vonoids [16]. Due to its powerful immune-modulating
properties [17], formulations of mistletoe extracts such as
Iscador, Helixor, Eurixor, Isorel have been used in oncol-
ogy for many years [18]. Plants belonging to the Genus
Elytranthe have shown substantial antitumor potential in
previous studies [19, 20]. Earlier investigations on Ely-
tranthe parasitica have focussed on their anti-tumour
potential in Ehrlich Ascites Carcinoma model in Swiss
albino mice [21] and against human breast adenocarcin-
oma cell line, MCF-7 [22]. We believe this is the first
report exploring the cytotoxic effects of EP stem extract/
fractions on HepG2 hepatocellular carcinoma cell line.
Methods
Chemicals and reagents
Petroleum ether, diethyl ether, butanol and toluene were
purchased from Finar Limited, Ahmedabad, India. Ethanol
was procured from Hayman Ltd, Essex, UK. Methanol,
ethyl acetate and glacial acetic acid were purchased from
Merck Specialties Pvt Ltd, Mumbai, India. Dulbecco’s
Modified Eagle’s medium, Fetal Bovine Serum, Gentamy-
cin, Sulforhodamine B (SRB), acridine orange, ethidium
bromide, Folin Dennis reagent and gallic acid were ob-
tained from Sigma Aldrich, St Louis, USA. Tris base and
trypsin-EDTA were purchased from HiMedia Laboratories
Pvt. Ltd, Mumbai, India. Trichloroacetic acid and sodium
carbonate was purchased from Nice Chemicals Pvt Ltd,
Kochi. Tissue culture flasks, multi-well plates and petri
plates were obtained from Sigma Aldrich, St Louis, USA.
Plant extraction
Stem of Elytranthe parasitica (EP) was collected from
Manipal, Karnataka, India. The plant was authenticated
by Dr. Gopalakrishna Bhat, Professor and Head, Depart-
ment of Botany, Poornapraja College, Udupi, Karnataka,
India. A voucher specimen (PP 565) has been deposited
in the museum of Department of Pharmacognosy, Manipal
College of Pharmaceutical Sciences, Manipal for future ref-
erence. EP stem (5 kg) was shade-dried, coarsely powdered
and extracted with methanol by Soxhlet extraction to
obtain the methanol extract (EP.M). After completion of
extraction, the extract was concentrated under reduced
pressure and controlled temperature and stored in the des-
iccator until further use.
Preparation of fractions
The methanol extract of stem (200 g) of EP was fraction-
ated sequentially with solvents petroleum ether, diethyl
ether, ethyl acetate, butanol and water [23] to obtain pet-
roleum ether fraction (EP.PE), diethyl ether fraction
(EP.DEE), ethyl acetate fraction (EP.EA), butanol fraction
(EP.But) and aqueous fractions (EP.Aq) respectively. All
fractions were concentrated on a rotary evaporator to
complete dryness and their percentage yield was calcu-
lated. The fractions were stored at 4 °C until further use.
Cell line and culture condition
Human hepatocellular carcinoma cell line (HepG2) and
normal kidney epithelial cell line (Vero) were obtained
from National Center for Cell Sciences (NCCS), Pune.
The cells were cultured in DMEM (Dulbecco’s Modified
Eagle’s medium) supplemented with 10 % FBS. The cells
were maintained at a constant temperature of 37 °C and
under humidified conditions (in 5 % CO2) in an
incubator.
Cytotoxicity screening by Sulforhodamine B assay (SRB)
Cytotoxicity of EP extract and fractions were determined
by Sulforhodamine B (SRB) assay [24]. Briefly, exponen-
tially growing HepG2 cells were seeded into 96-well
plates (5000 cells/well in 100 μL of media) and incu-
bated for 24 h. Prior to the experiment, the test
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compounds were prepared in DMSO and diluted with
media serially to obtain appropriate concentrations.
Cells were treated with the extracts and fractions at con-
centrations of 25, 50, 100 and 200 μg/mL and incubated
for 48 h. HepG2 cells in control group were treated with
media containing 0.25 % DMSO. All treatments were
carried out in triplicate. After 48 h of incubation from
treatment period, to each well 100 μL of 10 % ice –cold
trichloroacetic acid was added gently. The plate was sub-
sequently incubated for an hour at 4 °C. Following this,
the plate was sharply flicked, washed four times with
200 μL of deionized water and air dried. The plate was
stained by adding 100 μL Sulforhodamine B (0.057 % w/v
in 1 % acetic acid) and kept for 30 min in the dark at room
temperature. Subsequently, the unbound dye was rapidly
removed by rinsing four times with 1 % w/v acetic acid.
The plate was air dried and excess water was removed by
tapping on a tissue paper. 100 μL of 10 mM unbuffered
Tris base was added to each well to solubilize the dye.
The plate was shaken in a gyratory mixer with agita-
tion for 10 min. Finally, absorbance was measured
using spectrophotometer at 570 nm followed by the
calculation of percentage cell viability and IC50 values
using the following formula: Percentage cell viability =
100 – [((A-B)/A) × 100], where A = Absorbance of cells
treated with 0.25 % DMSO medium, B = Absorbance of
cells treated with extracts. Doxorubicin and gallic acid
were used as standards.
Total pro-oxidant potential
The potential of EP extract/fractions to impede DNA
degradation mediated by the hydroxyl radicals was eval-
uated using the copper-1, 10 - phenanthroline complex
method [25, 26] with slight modification. Accordingly,
1.2 mL of the reaction mixture comprising 100 μL of
9 mM 1, 10-phenanthroline, 240 μL of 5 M CuCl2.2H2O,
100 μL of 1 mg/mL DNA, 460 μL of 100 mM KH2PO4–
KOH buffer (pH 7.4) was prepared. To it, 100 μL of
2.88 mM ascorbic acid or 100 μL of EP extract/ fraction
(at a concentrations of 0.1, 1, 5 and 10 mg/mL) were
added. The reaction mixture was subsequently incubated
for one hour at 37 °C for 60 min. Afterwards, the follow-
ing reagents were added in a sequential order: 100 μL of
0.1 M EDTA, 1 % (w/v) Thiobarbituric acid (in 0.05 M
NaOH) and 1 mL of 25 % (v/v) HCl. Subsequently, the
test samples were mixed in a vortexer and heated on a
water bath for an hour at 100 °C. They were conse-
quently cooled by immersing into an ice-water bath. To
each test sample, 1.5 mL of n-butanol was added and
the combination was mixed in the vortexer. Following
this, the absorbance of the upper n-butanol layer was re-
corded at 530 nm. All experiments were performed in
triplicate and data was presented as mean absorbance
values and mean % inhibitory capacity (n = 3). Ascorbic
acid was used as reference standard. Reaction mixtures
with no test samples/standard served as control (100 %
TBARS).
Visualization of apoptosis by dual AO/EB staining
A chief hallmark of cancer cells is their adeptness to
evade apoptosis and in consequence grow incessantly.
Staining techniques such as AO/EB staining can dis-
tinctly detect the mode of cell death i.e. if cells have
undergone cell death by apoptosis or necrosis [27]. AO/
EB staining was done as per the standardized protocol
[28]. Briefly, HepG2 cells (50,000 cells/well) in exponen-
tial phase were seeded onto 6-well plates and kept for
24 h incubation. The cells were treated with the test
samples and incubated for 48 h. Subsequently, media
was removed and 1 mL of 70 % ice cold ethanol was
added to each well. The plate was kept for 2–4 h at 4 °C.
Following this, ethanol was removed from the plate sur-
face and rinsed with Phosphate buffered saline (PBS).
The cells were stained with 300 μL of acridine orange/
ethidium bromide dye (1 mg/mL) for 20 min. Thereafter,
the dye was washed with PBS two times. The cells were
observed under fluorescent microscope (Zeiss, Germany)
and morphology of cells was observed. Untreated
HepG2 cells and Curcumin treated HepG2 cells served
as the control and standard groups respectively. Viable
and apoptotic cells were counted and represented as
mean ± SEM.
Phytochemical constitution of EP
Preliminary phytochemical screening and thin layer
chromatographic studies
EP extract and fractions were screened for their phyto-
constituents [29]. Further, thin layer chromatography
was performed alongside reference standard gallic acid
in Toluene: Ethyl acetate: Formic acid: Methanol
(3:3:0.8:0.2) [30].
Total phenolic content
Folin-Ciocalteu method was utilized to measure the total
phenolic content of EP extract and fractions as per the
standard protocol [31].
Total flavonoid content
Aluminium chloride colorimetric method was followed
to determine the total flavonoid content in EP extract
and fractions [32].
Total tannin content
Folin Denis method was employed to detect the pres-
ence of tannins in the investigational plant [33].
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High performance thin layer chromatography
fingerprinting
Gallic acid was quantified in EP extract and fractions by
HPTLC fingerprinting [30]. Briefly, test solutions of EP
extract/fractions were prepared at a 2 mg/mL concentra-
tion in methanol. Gallic acid solution was prepared at a
concentration of 100 μg/mL in methanol. HPTLC
Silica gel 60 F254 plate (Merck Life Sciences Ltd Pvt,
Mumbai) with a dimension of 20 cm x 10 cm served
as the stationary phase. Mobile phase was prepared by
saturating the 20 cm x 10 cm Twin trough chamber
with 10 mL of Toluene: Ethyl acetate: Formic acid:
Methanol (3:3:0.8:0.2) for twenty minutes. Using the
Camag Linomat 5 sample applicator, outfitted with li-
quid nitrogen tank, 10 μL per sample/standard was
sprayed in the form of bands onto the HPTLC plate at
a distance of 1.5 mm from the plate base. Sample solu-
tions were loaded onto the sample applicator with a
100 μL HPTLC syringe (Camag Linomat syringe
695.0014, Hamilton Bonaduz, Schweiz). The plate was
air dried and developed in the Twin trough chamber
up to a distance of 80 mm from the point of applica-
tion. Using Camag TLC Scanner 3, the HPTLC plate
was scanned densitometrically under a scanning speed of
20 mm/s at a single wavelength of 280 nm. Subsequently,
UV absorption spectrum of bands corresponding to gallic
acid was examined at the same wavelength.
Statistical analysis
Results are expressed as Mean ± Standard Error of Mean
(SEM). GraphPad Prism 5.0 software (GraphPad Soft-
ware, Inc., California) was utilized for preparing graphs
and for estimation of IC50 via the non linear regression
equation. Statistical significance (P value) was ascer-
tained by one-way ANOVA, followed by Tukey’s post
hoc test of significance between different groups, where,
P < 0.05 was estimated to be significant.
Result and discussion
Effects of EP extract/fraction on HepG2 and Vero cells
EP extract/fractions were tested against HepG2 hepato-
cellular carcinoma cell line and Vero (normal kidney
epithelial) cells using SRB assay. SRB assay, which was
originally, developed by Skehan et al in 1990 gives an
accurate and reproducible measurement of the cellular
protein content. It works primarily on the principle of
the pink aminoxanthine SRB dye binding to the basic
amino acid residues of the proteins present in the cell
[34]. Of the tested samples, fractions EP.DEE and EP.EA
were found to be most active against HepG2 cell line
with an IC50 of 56.7 ± 7.8 μg/mL and 101.33 ± 5.3 μg/mL
respectively (Fig. 1a). The active fractions also displayed
concentration-dependent inhibition of cell growth
(Table 1). EP.M showed moderate cytotoxicity against
HepG2 carcinoma cell line (IC50 = 154.12 ± 2.6 μg/mL).
The remaining fractions, EP.PE, EP.But and EP.Aq were
unable to prevent cell proliferation at very high concentra-
tions and were considered to be inactive. Doxorubicin, the
standard used presented significantly high cytotoxicity
with an IC50 of 1.9 ± 0.3 μM. Several studies have proven
gallic acid, a predominant polyphenol to possess remark-
able anti-cancer activity [35]. Gallic acid was identified in
the EP extract and fractions by Thin Layer Chromatog-
raphy. Due to its confirmed presence in the plant, we
employed gallic acid as the second standard in the assay
to study if the cytotoxic activity of EP could partially be at-
tributed to the presence of gallic acid. We observed gallic
acid to exhibit potent cytotoxic activity against HepG2
cell line in a dose-dependent manner (IC50 = 31.05 ±
6.2 μg/mL). Our results concurred with previous stud-
ies [36, 37] which investigated the cytotoxic activity of
gallic acid against HepG2 cell line. At the highest tested
concentration (400 μg/mL), EP fractions and extract
did not exert cytotoxic effects on Vero cells (Fig. 1b).
Pro-oxidant potential of EP extract/fractions
Several plants enriched with polyphenols are known to
possess dual anti-oxidant effects at low concentrations
and pro-oxidant effects against DNA at higher concen-
trations [38]. EP extract/fractions were assessed for their
pro-oxidant and anti-oxidant effects using copper phe-
nanthroline induced DNA damage assay. In control
group, DNA was heated with the (1, 10- phenanthroline)
Cu (II) complex which resulted in the production of
TBARS that is evidenced by the increase in absorbance.
Ascorbic acid at all concentrations (10, 100, 500 and
1000 μg/mL) considerably augmented the quantity of
hydroxyl radical-generated TBARS from the basal level.
At 10 μg/mL, EP.M did not increase absorbance above
the basal level; however at 100, 500 and 1000 μg/mL,
the absorbance was higher than control. EP.PE exhibited
high absorbance at the highest tested concentration of
1000 μg/mL. There was increased absorbance in EP.DEE,
EP.EA and EP.But fraction at higher concentrations of 500
and 1000 μg/mL. EP.Aq exhibited lesser absorbance than
control at all concentrations (Table 2). Clearly, EP.M,
EP.DEE, EP.EA and EP.But have anti-oxidant effects at
lower concentrations of 10 and 100 μg/mL and pro-
oxidant effects at 500 and 1000 μg/mL (Fig. 2).
1, 10 copper phenanthroline assay is a frequently used
assay to examine the pro-oxidative activity of extracts
against DNA [26]. On addition of reagents and subse-
quent incubation, a complex called bis (1, 10 – phenan-
throline copper) is formed which links to DNA and
breaks down its strand; hydroxyl radical generation is
primarily implicated in DNA damage [39]. However, if
the cuprous ions are bound, DNA degradation does not
occur. When reducing agent ascorbic acid (which is a
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proven pro-oxidant at higher concentration [40]) is
added to the complex, Cu(II) in the complex gets con-
verted to Cu(I) and hence, there is additional production
of hydroxyl radicals that breaks down DNA into TBARS
(Thiobarbituric Acid Reactive Substance). Hence, the
level of TBARS formed in different extracts/fractions
can indirectly reveal the quantity of hydroxyl radicals
generated and give an estimation of the pro-oxidant or
anti-oxidant activity of the extract/fractions at varying
concentration. ROS (Reactive Oxygen Species) often per-
sonate a “double edged sword” in chemotherapy [41].
While in the initial stages of cancer, they may contribute
to malignant transformation; in the more advanced
stages of cancer, ROS can exert cytotoxic effect on the
malignant cells. Normal cells may generally be spared
from this fate as they have comparatively low basal levels
of ROS. The ROS threshold level is therefore higher in
cancer cells and once this level is reached, apoptosis is
preferentially triggered in cancer cells alone, thereby pre-
venting the metastasis of cancer to vital organs [42].
However, to evade apoptosis, cancer cells often adapt
their anti-oxidant defense in response to the high oxida-
tive stress and so become drug resistant [43]. Recently,
several studies have investigated how the level of pro-
oxidants agents can be manipulated by redox modula-
tion and ROS mediated mechanisms to exclusively target
cancer cells to go into a state of apoptosis and prevent
cancer cells from becoming drug resistant [44, 45]. How-
ever, to wholly exploit the ROS-mediated cell-death mech-
anism as a treatment strategy against anticancer resistant
cancer cells, combinations of ROS generating compounds
with agents that suppress the cellular antioxidant capacity
could be employed against cancer cells [42]. Our prelimin-
ary findings from copper phenanthroline mediated DNA
damage assay indicate that EP fractions (EP.DEE, EP.EA,
EP.But) and EP.M exhibit substantial ROS generating cap-
acity at higher concentrations.
Pro-apoptotic effects of EP active fraction
Apoptosis is a highly synchronized process of cell death,
wherein cell fragments shrink to form ‘apoptotic bodies’
that are eventually phagocytosed by the nearby cells.
However, due to the numerous mutations they harbor,
cancer cells are adept at evading apoptotic process to
thwart their self-destruction [46]. Cytotoxic compounds
which selectively initiate apoptosis in cancer cells and
Table 1 Effect of EP extract/fractions on % cell viability of HepG2 carcinoma cell line by SRB assay
Concentration (μg/mL) EP.M EP.PE EP.DEE EP.EA EP.But EP.Aq Gallic acid
0 100.00 ± 0.33 100.00 ± 0.33 100.00 ± 0.33 100.00 ± 0.33 100.30 ± 0.33 100.30 ± 0.30 100.30 ± 0.30
25 96.80 ± 2.40 99.20 ± 5.60 59.30 ± 6.70 80.00 ± 0.50 99.60 ± 5.50 99.80 ± 4.50 53.80 ± 5.66
50 72.30 ± 5.50 99.00 ± 2.10 53.70 ± 11.90 63.10 ± 1.22 99.30 ± 3.80 99.10 ± 2.30 42.90 ± 9.20
100 69.00 ± 3.70 98.40 ± 0.40 40.90 ± 5.60 50.20 ± 4.40 94.80 ± 3.10 98.30 ± 1.50 33.50 ± 4.90
200 42.50 ± 2.10 86.00 ± 9.10 36.60 ± 3.98 38.90 ± 6.20 91.60 ± 7.80 93.00 ± 4.10 24.90 ± 6.89
400 16.40 ± 7.20 83.00 ± 9.00 20.90 ± 7.10 22.90 ± 3.10 72.40 ± 5.40 86.00 ± 3.20 20.70 ± 4.62
IC50 154.10 ± 2.60c > 200 56.70 ± 7.80a 101.30 ± 5.3b > 200 > 200 31.00 ± 6.21a
Results are expressed as mean ± SEM (of three observations) and analyzed using one-way ANOVA followed by Tukey’s post hoc test of significance [where different
alphabets a-cdenote significant difference (p <0.05)]. EP.M Methanol extract, EP.PE Petroleum ether fraction, EP.DEE Diethyl ether fraction, EP.EA Ethyl Acetate
fraction, EP.But Butanol fraction, EP.Aq Aqueous fraction
Fig. 1 Effect of EP extract/fractions on cell viability and growth of (a) human HepG2 hepatocellular carcinoma cells and (b) Vero cell line. HepG2
and Vero cells were seeded onto 96 well plate at a density of 5,000 cells/well and subsequently treated with EP extract/fractions for 48 h. Data is
expressed as IC50 (mean ± SD) of three individual experiments. Cell viability was estimated by Sulforhodamine B assay. EP. DEE- Diethyl ether
fraction, EP.EA- Ethyl Acetate fraction, EP.M- Methanol extract
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thus slow down their growth are considered to be poten-
tial candidates for chemotherapy [47]. Acridine orange
(AO) and ethidium bromide (EB), two fluorescent DNA
binding dyes (which differentially infiltrate the cells
emitting green and red fluorescence respectively) are
used in AO/EB staining to detect apoptosis-related
transformations in the cell membrane during apoptosis.
Per se, the technique distinguishes between viable, early
apoptotic, late apoptotic and necrotic cells [27]. Both
AO and EB intercalate with DNA and stain the cell nu-
clei differently. While AO is cell permeable and stains
the nuclei of viable cells and early apoptotic cells green,
EB is impermeable to cells with an intact cell membrane.
EB solely enters cells with damaged and compromised
cell membrane and stain the nuclei orange [48].
HepG2 cells treated with active EP fraction, EP.DEE
underwent considerable cytoplasmic shrinkage com-
pared to untreated cells (Fig. 3). Other distinctive traits
of apoptosis such as condensed chromatin and appear-
ance of apoptotic bodies were spotted in EP.DEE treated
group. Apoptotic cells were identified by their bright
yellowish-green fluorescence and typical crescent- like
appearance on one side of the cell. HepG2 cells treated
with lower concentration of active fraction appeared
bright yellowish-green indicating the cells to be in early
apoptotic stage of cell death. Cells subjected to higher
concentration of active fraction had more number of
bright yellowish-green apoptotic cells. Untreated cells
(in control group) were consistently green in color, with
normal morphological features and undamaged cell
membrane. Curcumin-treated cells were stained a bright
yellowish green also indicating apoptotic death of cells.
Treatment with high concentrations of active fraction
did not cause necrosis; hence mode of cell death of
treated HepG2 cells was ascertained to be via apoptosis.
Phytochemical profiling of EP
Phytochemical screening results
EP extract and fractions were screened for the presence
of secondary metabolites. EP.M, EP.PE and EP.DEE gave
a positive test for Liebermann-Burchard and Salkowski
test revealing phytosterols. EP.DEE, EP.EA and EP.But
gave an instant crimson red color in Shinoda’s test, im-
plying presence of flavonoids in these fractions. EP.M,
EP.DEE, EP.EA, EP.But and EP.Aq tested positive
(greenish-black color) for Ferric chloride test for phenols
and tannins. Saponins and caarbohydrates were detected
in EP.M extract and EP.Aq fraction.
Fig. 2 % Inhibitory effect of EP extract/fractions in hydroxyl radical mediated DNA degradation assay. The test compounds were screened at
concentrations of 10, 100, 500 and 1000 μg/mL (from left to right). Ascorbic acid was employed as standard at the same concentrations. Results
are expressed as % inhibitory capacity (mean ± SD) of three individual experiments. Statistical Analysis was performed by 2 way ANOVA followed
by Bonferroni’s post hoc test of significance. Columns with similar superscripts did not differ significantly (P > 0.05). EP. M- Methanol extract, EP.PE
-Petroleum ether fraction, EP. DEE- Diethyl ether fraction, EP.EA- Ethyl Acetate fraction, EP. But - Butanol fraction, EP.Aq- Aqueous fraction
Table 2 Effect of EP extract/fraction on copper - 1, 10 - phenanthroline dependent DNA damage
Concentration (μg/mL) Extent of DNA damage (A530nm)
Test compounds EP.M EP.PE EP.DEE EP.EA EP.But EP.Aq Ascorbic acid
10 0.04 ± 0.001 0.04 ± 0.008 0.04 ± 0.004 0.04 ± 0.002 0.04 ± 0.004 0.03 ± 0.004 0.08 ± 0.004
100 0.06 ± 0.005 0.04 ± 0.004 0.07 ± 0.004 0.04 ± 0.001 0.04 ± 0.002 0.07 ± 0.002 0.10 ± 0.009
500 0.12 ± 0.001 0.04 ± 0.007 0.08 ± 0.002 0.13 ± 0.002 0.13 ± 0.004 0.05 ± .0.001 0.18 ± 0.007
1000 0.22 ± 0.002 0.11 ± 0.001 0.10 ± 0.002 0.18 ± 0.003 0.17 ± 0.008 0.04 ± 0.001 0.30 ± 0.007
Control 0.06 ± 0.003
Values are expressed as mean ± SEM (of three observations). EP.M Methanol extract, EP.PE Petroleum ether fraction, EP.DEE Diethyl ether fraction, EP.EA Ethyl
Acetate fraction, EP.But Butanol fraction, EP.Aq Aqueous fraction
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Phenol, flavonoid and tannin content
Polyphenols are a diverse group of phytoconstituents
comprising anthocyanins, isoflavonones, flavonoids, tan-
nins and catechins. Myriad of health benefits have been
attributed to this group of phytoconstituents largely due
to their key role in protecting the human body against
multiple diseases. In the past, several epidemiological
studies have investigated the chemopreventive effects of
polyphenols against various malignancies [49]. Flavo-
noids and tannins, two sub types of polyphenolic com-
pounds have been widely acknowledged to possess
remarkable anticancer potential. Since, polyphenols are
credited with such remarkable anticancer properties; we
endeavored to estimate the total phenolic, flavonoid and
tannin content in the plant extract/fractions to explore
any relation between their occurrence and the chemo-
therapeutic potential of the plant.
Gallic acid was used as the reference standard for deter-
mining total phenolic content by Folin-Ciocalteau method
and a calibration curve was plotted (R2 = 0.9981). EP.EA
and EP.DEE fractions were found to be highly enriched
with phenolic compounds with an estimated phenolic
content of 91.01 ± 2.68 and 72.48 ± 2.43 mg GAE/g of
plant fraction respectively. For estimation of flavonoid
content by aluminium chloride colorimetrc method, quer-
cetin was employed as the reference standard and used in
concentrations ranging from 15.625 to 500 μg/mL to plot
a calibration curve (R2 = 0.999). Highest flavonoid content
Fig. 3 Visualization of apoptosis in HepG2 hepatocellular carcinoma cells after treatment (AO/EB dual staining) HepG2 cells were seeded onto 6
well plates at a density of 50,000 cells/well, treated with test compounds and stained with AO/EB dye after 48 h of treatment. The treatment
groups are as follows: (a) Control or untreated HepG2 cells (b) Curcumin reference group (4 μg/mL) (c) EP. DEE (15 μg/mL) (d) EP. DEE (30 μg/mL).
Arrows in the figure are directed towards the apoptotic bodies, that exhibited bright yellowish-green fluorescence. Condensed chromatin
was observed in all treated groups. Control group cells showed normal morphological features with undamaged cell membrane. e Graph
depicting number of apoptotic cells in different treatment groups. *P value > 0.05 when compared to control group. Columns with different
superscripts differ significantly (P > 0.05). EP. DEE- Diethyl ether fraction
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was observed in EP.DEE (14.41 ± 0.52 mg QE/g of plant
fraction). EP.EA also had sufficiently high flavonoid con-
tent (12.93 ± 0.65 mg QE/g of plant fraction). For tannin
content estimation by Folin-Dennis method, gallic acid
was used as the positive control. Calibration curve of gallic
acid was plotted to estimate the tannin content in EP ex-
tract and fractions (R2 = 0.9995). The level of tannins in
EP extract and fractions, estimated by Folin–Dennis
method and expressed in Gallic acid Equivalent (GAE)
were similar to the level of phenolics quantified by Folin-
ciocalteau method. The highest content of tannin was
found in fractions EP.EA (22.80 ± 0.19 mg GAE/g of plant
fraction) and EP. DEE (17.10 ± 0.13 mg GAE/g of plant
fraction). Sufficiently high tannin content was noted in the
butanol fraction (13.57 ± 0.20 mg GAE/g of plant frac-
tion). Table 3 lists the total phenol, flavonoid and tannin
content in EP extract and fractions.
High performance thin layer chromatographic
fingerprint profile
High Performance Thin Layer Chromatography with
gallic acid as reference standard afforded well resolved
peaks in EP extract and fractions, with good separation
of gallic acid from other phytoconstituents. Figure 4
depicts the HPTLC fingerprint profile of EP extract and
Table 3 Total phenol, flavonoid and tannin content in EP extract/fractions
S. No. Extracts/fractions Total phenol content
(mg GAE/g of plant extract)
Total flavonoid content
(mg QE/g of plant extract)
Total tannin content
(mg GAE/ g of plant extract)
1. EP.M 66.97 ± 4.78b 10.87 ± 0.85b 7.18 ± 0.12
2. EP.PE 36.85 ± 1.05d 12.97 ± 1.55b 4.37 ± 0.15
3. EP.DEE 84.38 ± 1.55a, c 15.72 ± 2.85a,b 17.10 ± 0.13a
4. EP.EA 92.17 ± 4.48a 22.48 ± 1.51a 22.80 ± 0.19a
5. EP.BUT 77.43 ± 6.25b, c 12.29 ± 5.32b 13.57 ± 0.20
6. EP.AQ 31.56 ± 1.47d 2.29 ± 0.21 0.64 ± 0.09
Data is presented as mean ± SEM (n = 3); Equivalent. Results were analyzed by one way ANOVA followed by Tukey’s test. Values in the same column followed by a
different superscript a-dare significantly different (P < 0.05). GAE Gallic acid Equivalent, QE Quercetin, EP.M Methanol extract, EP.PE Petroleum ether fraction, EP.DEE
Diethyl ether fraction, EP.EA Ethyl Acetate fraction, EP.But Butanol fraction, EP.Aq Aqueous fraction
Fig. 4 HPTLC fingerprint profile of EP extract and fractions (a) EP.M, Methanol extract (b) EP.PE, Petroleum ether fraction (c) EP. DEE, Diethyl ether
fraction (d) EP.EA, Ethyl acetate fraction (e) EP. But, Butanol fraction (f) EP.Aq, Water fraction fraction (g) Gallic acid (reference standard)
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fractions. Reference standard gallic acid eluted at Rf
(Retention factor) of 0.63. Gallic acid was detected in EP
extract and bioactive fractions, EP. DEE and EP.EA.
EP.DEE, the active fraction gave mainly eleven peaks, of
which gallic acid was peak no. 7 (Rf value - 0.63, 2.173 ±
0.053 %). EP.EA gave eleven peaks, of which gallic acid
was peak no. 10 (Rf value - 0.63, 0.528 ± 0.01 %). EP
methanol extract also contained gallic acid, however in
comparatively less quantity (peak no 7, Rf value - 0.63,
0.293 ± 0.016 %). Gallic acid was not observed in
other EP fractions EP PE, EP.But and EP.Aq. To con-
firm the presence of gallic acid in EP, the UV
spectrum of gallic acid at 280 nm was compared with
the corresponding peak (at Rf 0.63) in EP extract/
fraction. The UV spectral characteristics matched,
verifying the presence of gallic acid in EP.M, EP. DEE
and EP.EA (Fig. 5).
It is widely accepted that the additive and synergistic
anti-cancer effect of plant extracts are hugely due to the
multiple bioactive substances present in them [49].
Often, individual components isolated from plant exert
sufficiently lower activity than the combined plant ex-
tract. Per se, the anticancer activity of EP maybe primar-
ily attributed to the synergistic activity of the plentiful
phyto components present in the plant, one of which is
gallic acid. Our research work indicates that gallic acid
maybe one of the phytoconstituents that contributes to
the overall anti-tumor potential of EP. Gallic acid, a
principal polyphenolic molecule that occurs naturally in
several plant based foods has been credited with remark-
able anti-tumor activity [35]. Several studies have proven
gallic acid to exhibit potent in vitro cytotoxic activity
against various cancer cell lines of lung, cervix, liver etc
[35]. Among the liver cancer cell lines, gallic acid in-
duced apoptosis in SMMC-7721 hepatocellular carcin-
oma cell line via the mitochondrial mediated pathway by
various mechanisms involving activation of pro-enzymes
caspase 3 and caspase 9, induction of ROS pathway, in-
hibition of mitochondrial membrane potential (MMP)
and upregulation of Bcl-2-like protein [36]. Moreover,
gallic acid showed 3-fold higher sensitivity towards hep-
atic cancer cell lines HepG2 and SMMC-7721 when
compared to normal hepatocyte cell line HL-7702
[36, 50]. The underlying Structure Activity Relation-
ship (SAR) of gallic acid’s selective anticancer activity
was due to its carboxyl group which differentiated be-
tween cancer and non-cancerous cells and so exclusively
triggered apoptosis in cancer cells [51]. Several studies
have also indicated gallic acid to possess potent pro-
oxidant potential [52]. Hence, presence of gallic acid may
partially be responsible for the cytotoxic and pro-oxidant
potential of EP extract/fractions.
Fig. 5 Overlay of UV absorption spectra of reference gallic acid and corresponding band in EP extract/fractions [Absorbance, AU vs. Wavelength,
nm] (a) Gallic acid and EP.M extract (b) Gallic acid and EP. DEE (c) Gallic acid and EP.EA
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Conclusion
EP.DEE, the active fraction was found to be highly toxic
against HepG2 cell line and also exhibited high pro-
oxidant potential akin to ascorbic acid. Phytochemical
characterization studies in EP revealed presence of poly-
phenols in the plants with especially higher flavonoid,
tannins and phenolic content in the active fractions EP.
DEE and EP.EA. Gallic acid was identified and quanti-
fied in active fractions. Our findings further corroborate
that EP.DEE caused cell death in HepG2 cells via apop-
tosis, signifying the fraction to be a promising contender
in treating HCC. However, further studies to comprehend
the underlying molecular mechanism for its anti-cancer
activity are requisite for establishing its effectiveness in
HCC therapy. Studies on identification and isolation of
other bioactive phytoconstituents from EP are being in-
vestigated in our lab presently.
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